Stock AURINIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Aurinia Pharmaceuticals Inc. Toronto S.E.

Equities

CA05156V1022

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aurinia to Participate in Upcoming Investor Healthcare Conferences
BU
Aurinia Pharmaceuticals : 2024 Proxy Supplement
PU
Aurinia Announces 2024 Annual General Meeting Results
BU
AURINIA PRESENTS SAFETY AND EFFICACY PROFILE OF LUPKYNIS FOR PEOPLE WITH LUPUS NEPHRITIS AT EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY CONGRESS 2024
AQ
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
BU
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
BU
Aurinia Provides Update on Proxy Statement
BU
Aurinia Pharmaceuticals : Modern Slavery Report
PU
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
BU
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
BU
AURINIA PRESENTS DATA REINFORCING LUPKYNIS SAFETY AND EFFICACY FOR PEOPLE WITH LUPUS NEPHRITIS AT CONGRESS OF CLINICAL RHEUMATOLOGY EAST 2024
AQ
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
BU
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
BU
Aurinia: Q1 Earnings Snapshot
AQ
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
BU
AURINIA PHARMACEUTICALS - THE U.S. FOOD & DRUG ADMINISTRATION APPROVES UPDATED LUPKYNIS LABEL TO INCLUDE LONG-TERM DATA FROM THE AURORA CLINICAL PROGRAM
AQ
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
BU
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
BU
UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE
AQ
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AUPH Stock
  4. Stock
  5. News Aurinia Pharmaceuticals Inc.
  6. Press Releases